Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 372

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1A
Chunk 372
---
 patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment
to us, result in our inability to manufacture or commercialize product candidates without infringing third-party patent rights or
result in our breach of agreements pursuant to which we license such rights to our collaborators or licensees. In addition, if the breadth
or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating
with us to license, develop or commercialize current or future product candidates. Such challenges may result in loss of exclusivity
or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others
from using or commercializing similar or identical technology and product candidates, or limit the duration of the patent protection
of our technology and product candidates. Such challenges also may result in substantial cost and require significant time from our scientists
and management, even if the eventual outcome is favorable to us. Any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations and prospects.

69

Even if they are unchallenged, our owned and licensed patents and pending
patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent
claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in a non-infringing manner.
For example, a third party may develop a competitive product that provides benefits similar to one or more of our product candidates but
that falls outside the scope of our patent protection. Moreover, patents have a limited lifespan. In the United States, the natural
expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent,
and the protection it affords, is limited. Without patent protection for our current or future product candidates, it may be open to competition
from generic versions of such product candidates. Given the amount of time required for the development, testing and regulatory review
of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.
As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing
product candidates similar or identical to our own and, which could have a material adverse effect on our business, financial condition,
results of operations and prospects.